Answers are grounded in this paper and cite their sources.
Helicobacter pylori (H. pylori) is a major cause of chronic gastritis, gastric ulcers and gastric cancer. Recent studies have identified that probiotics are beneficial to human health due, in part, to their anti‑H. pylori activities. Therefore, the present study investigated the antagonistic and local immunoregulatory activities of seven commercial probiotic strains and explored their mechanisms of actions. The human gastric epithelial cell line‑1 (GES‑1) was used to assess the effects of probiotics on the adhesion ability of H. pylori. GES‑1 cells were infected with H. pylori plus lipopolysaccharide (HP‑LPS) or the drug‑resistant H. pylori strain (HP021) in the presence or absence of live probiotics. Following this, the growth rate and the adhesion ability of GES‑1 cells were detected using MTT and urease activity assay. Toll‑like receptor 4 (TLR4), NFKB inhibitor‑α (IκBα) and nuclear factor (NF)‑κB levels were measured by western blot analysis. The amount of interleukin (IL)‑8 in the cell culture medium was determined by ELISA. Amongst the seven probiotic strains studied, live Lactobacillus acidophilus (L. acidophilus) and Lactobacillus bulgaricus (L. bulgaricus) inhibited H. pylori adherence to GES‑1 cells most significantly. L. bulgaricus inhibited IL‑8 production by GES‑1 cells through modulation of the TLR4/IκBα/NF‑κB pathway. Therefore, the present results suggested that consumption of food containing L. acidophilus and L. bulgaricus may be used as an adjuvant therapy for H. pylori‑associated gastritis.
No takes yet. Share an insight, caveat, or question.
Song et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: